Evolution Wealth Advisors’s Amicus Therapeutics FOLD Stock Holding History

Evolution Wealth Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-482	Closed	-$5K	–	335
2021 Q3	$5K	Sell	482 -375	-44%	-$3.84K	﹤0.01%	508
2021 Q2	$8K	Buy	857 +69	+9%	+$674	﹤0.01%	441
2021 Q1	$8K	Sell	788 -142	-15%	-$2.2K	﹤0.01%	451
2020 Q4	$21K	Sell	930 -821	-47%	-$16.8K	﹤0.01%	260
2020 Q3	$25K	Hold	1,751	–	–	0.01%	250
2020 Q2	$26K	Hold	1,751	–	–	0.01%	185
2020 Q1	$16K	Buy	1,751 +556	+47%	+$5.29K	0.01%	167
2019 Q4	$12K	Buy	1,195 +1,085	+986%	+$9.93K	﹤0.01%	270
2019 Q3	$1K	Sell	110 -1,174	-91%	-$12.7K	﹤0.01%	459
2019 Q2	$16K	Buy	+1,284	New	+$16.3K	0.01%	143

Other funds holding FOLD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Evolution Wealth Advisors's FOLD Position: Q4 2021 in Review

Evolution Wealth Advisors sold out of Amicus Therapeutics (FOLD) in Q4 2021, closing a stake of 482 shares — an estimated $5K sold.

Evolution Wealth Advisors first reported a position in FOLD in Q2 2019 and held it in 10 quarters. The position peaked at $26K in Q2 2020. 223 funds tracked by Wall St. Rank hold FOLD as of Q4 2021.

Evolution Wealth Advisors reported no remaining Amicus Therapeutics position as of Q4 2021 after selling out during the quarter.
Evolution Wealth Advisors sold 482 Amicus Therapeutics shares in Q4 2021, an estimated $5K.
Evolution Wealth Advisors first reported a position in Amicus Therapeutics in Q2 2019 and held it in 10 quarters.
Evolution Wealth Advisors's Amicus Therapeutics position peaked at $26K in Q2 2020.
223 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2021.

Based on Evolution Wealth Advisors's 13F filing for Q4 2021, filed 28 Jan 2022.